Replimune Group Inc (REPL)

Currency in USD
19.07
-0.16(-0.83%)
Closed·
19.20+0.13(+0.68%)
·
REPL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
18.6919.50
52 wk Range
1.5023.54
Key Statistics
Prev. Close
19.23
Open
18.84
Day's Range
18.69-19.5
52 wk Range
1.5-23.54
Volume
1.96M
Average Vol. (3m)
2.48M
1-Year Change
107.2826%
Book Value / Share
2.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
REPL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.50
Upside
+33.72%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Replimune Group Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

7 Buy
0 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 25.50
(+33.72% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy27.00+41.58%14.00MaintainNov 16, 2026
Cantor Fitzgerald
Buy---MaintainOct 05, 2026
JPMorgan
Buy21.00+10.12%20.00MaintainAug 26, 2026
Cantor Fitzgerald
Buy---MaintainAug 12, 2026
JPMorgan
Buy20.00+4.88%17.00MaintainAug 07, 2026

Replimune Group Inc SWOT Analysis


Market Dynamics
Learn how Replimune navigates the competitive oncology landscape, leveraging its unique technology to differentiate itself in a growing biotech secto
Financial Outlook
Delve into Replimune's financial stability amidst negative EPS projections, with analysts setting an average price target of $8.60 per share
Pipeline Potential
Explore Replimune's ongoing clinical trials and expansion opportunities for RP1 in various cancer indications, showcasing the company's innovative approach
Regulatory Hurdles
Replimune faces FDA challenges for RP1 in melanoma treatment, impacting stock performance and future prospects in oncology therapies
Read full SWOT analysis

Replimune Group Inc Earnings Call Summary for Q2/2027

  • Replimune reported Q2 FY2026 loss of $0.54/share, beating consensus of $0.75 by 28%; zero revenue vs. $1M forecast due to timing.
  • TUDRIQEV commercial shipments began early October after quarter-end; over 70% of 200 target accounts engaged, 15+ institutions prescribing.
  • Cash position strengthened to $307.8M from $141M August offering; runway exceeds 12 months with commercial organization nearly fully staffed.
  • First product revenue expected in Q3 FY2026; no specific guidance provided. List price set at $450K per treatment course before rebates.
  • Permanent J-code anticipated by April 2027 to broaden adoption; company plans to double prescribing accounts by end of 2026.
Last Updated: 10/28/2026, 08:45 AM
Read Full Transcript

Earnings

Latest Release
Oct 28, 2026
EPS / Forecast
-0.54 / -0.75
Revenue / Forecast
-- / 1M
EPS Revisions
Last 90 days

REPL Income Statement

Compare REPL to Peers and Sector

Metrics to compare
REPL
Peers
Sector
Relationship
P/E Ratio
−6.7x−1.8x−0.2x
PEG Ratio
−0.34−0.050.00
Price / Book
8.8x2.4x2.6x
Price / LTM Sales
-8.4x2.6x
Upside (Analyst Target)
33.7%136.3%76.9%
Fair Value Upside
Unlock18.6%14.9%Unlock

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
21.44M22.61%408.79M
Other Institutional Investors
112.39M77.39%2.14B
Public Companies & Retail Investors
0.000.00%0.00
Total
133.83M100.00%2.55B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Baker Bros. Advisors LP11.65%11,045,336210,635
Baker Brothers Life Sciences, L.P.10.67%10,116,095192,914

People Also Watch

97.17
KOD
-0.75%
36.05
PENG
-15.20%
180.35
ALAB
-14.77%
145.83
GH
+0.16%
81.31
NBIS
-16.11%

FAQ

What Is the Replimune (REPL) Stock Price Today?

The Replimune stock price today is 19.07 USD.

What Stock Exchange Does Replimune Trade On?

Replimune is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Replimune?

The stock symbol for Replimune is "REPL."

What Is the Replimune Market Cap?

As of today, Replimune market cap is 1.82B USD.

What Is Replimune's Earnings Per Share (TTM)?

The Replimune EPS (TTM) is -2.78.

When Is the Next Replimune Earnings Date?

Replimune will release its next earnings report on Feb 02, 2027.

From a Technical Analysis Perspective, Is REPL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Replimune Stock Split?

Replimune has split 0 times.

How Many Employees Does Replimune Have?

Replimune has 465 employees.

What is the current trading status of Replimune (REPL)?

As of Nov 21, 2026, Replimune (REPL) is trading at a price of 19.07 USD, with a previous close of 19.23 USD. The stock has fluctuated within a day range of 18.69 USD to 19.50 USD, while its 52-week range spans from 1.50 USD to 23.54 USD.

What Is Replimune (REPL) Price Target According to Analysts?

The average 12-month price target for Replimune is 25.50 USD, with a high estimate of 31 USD and a low estimate of 19 USD. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +33.72% Upside potential.

What Is the REPL Premarket Price?

REPL's last pre-market stock price is 19.00 USD. The pre-market share volume is 11,560.00, and the stock has decreased by -0.23, or -1.20%.

What Is the REPL After Hours Price?

REPL's last after hours stock price is 19.20 USD, the stock has decreased by 0.13, or 0.68%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.